Caliper Life Sciences Inc

Caliper Life Sciences — Xenogen — SPAC Merger (June 2006)

19 slides from Caliper Life Sciences's SPAC merger presentation, Jun 15, 2006

  1. Slide 1: Transforming Life Sciences through Innovative Technologies

    Transforming Life Sciences through Innovative Technologies Tom Higgins Executive Vice President & CFO Mark Roskey, Ph.D. Vice President, Reagents and Applied Biology June 14, 2006

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation includes forward-looking statements, including financial projections. Reference to what we expect, believe, intend to do, plan, hope, estimate or other statements referring to future events or results are intended to identify those as forward-looking stat

  3. Slide 3: Important Notice

    Important Notice In addition to the foregoing, please note that Caliper has filed a draft Registration Statement on Form S-4 in order to register the shares of its common stock and warrants to be issued to the former stockholders of Xenogen Corporation in the proposed merger between Caliper and Xeno

  4. Slide 4: Rapid Evolution of our Business and Strategy

    Rapid Evolution of our Business and Strategy Transformative Event – Xenogen merger Molecular imaging Bridging in vitro/in vivo experimentation Revenue, cost synergies 2006 Forward Accelerating revenue growth Critical mass Drive to profitability Transformative Event – Zymark merger New management tea

  5. Slide 5: Emerging Caliper Profile – Revenue Mix and Growth

    Emerging Caliper Profile – Revenue Mix and Growth Revenue Percent Growth Outlook Pre Post 30% 20% 15%+/- 60% 40% 5%+/- 10% 7% 15%+/- 0% 33% 15%+ Pre-Xenogen Post-Xenogen LabChip products Liquid handling & automation In vitro services In vivo products and services 30% 60% 10% 20% 40% 7% 33%

  6. Slide 6: Markets: Profile of the New Company

    Markets Drug Discovery and Development $2.0B market, growing 5-8%; approx 6%+ share w/ Xenogen 2005 revenue approx. $80M; expect 2006 growth above market rate Molecular Diagnostics $1.5B market, growing 20%; new entrant 2005 license & contract revenue approx. $7M; expect product revenue in 2007 Prof

  7. Slide 7: One Reason for the Productivity Gap is Over-reliance on Early Stage In Vitro Testing

    One Reason for the Productivity Gap is “Over-reliance” on Early Stage In Vitro Testing Current industry trends which may help close the gap: Improved in vitro data quality Better correlation between in vitro and in vivo results, esp. clinical Identification of relevant biomarkers, and use of imaging

  8. Slide 8: Our Response: Increase the Clinical Relevance of Pre-clinical Experimentation

    In Vitro Molecule Analysis Cellular Analysis Humans Animal Models 1,000 days 10 days 10/day 1,000,000/day THROUGHPUT and COST/DATA POINT Relevance 1,000/day $10,000,000 $100,000 $1,000 $10 $0.01 PATIENT MOLECULE Our Response: Increase the Clinical Relevance of Pre-clinical Experimentation 100,000/da

  9. Slide 9: Our Response: Acquire, Innovate, Integrate Tools for Relevant Experimentation

    In Vitro Molecule Analysis Cellular Analysis Humans Animal Models 1,000 days 10 days 10/day 1,000,000/day THROUGHPUT and COST/DATA POINT Relevance 1,000/day $10,000,000 $100,000 $1,000 $10 $0.01 PATIENT MOLECULE Our Response: Acquire, Innovate, Integrate Tools for Relevant Experimentation 100,000/da

  10. Slide 10: In Vivo Technologies Play a Key Role in FDA Critical Path Research

    In Vivo Technologies Play a Key Role in FDA Critical Path Research Better Evaluation Tools – Developing New Biomarkers and Disease Models Genomics Proteomics Metabolomics Safety Biomarkers Surrogate End Points New Imaging Techniques New Animal Models

  11. Slide 11: Xenogen's Pioneering Use of Bioluminescence in Whole Animals

    Xenogen’s Pioneering Use of Bioluminescence in Whole Animals The luciferase gene is incorporated into cells or animals to tag biological functions with light Brain Lung Kidneys

  12. Slide 12: Integrated Solution for Biophotonic Imaging

    Integrated Solution for Biophotonic Imaging Proprietary System Biological Solutions Imaging Hardware Imaging Software Tag Cell Tag Gene

  13. Slide 13: Comparison of Current Methods and Xenogen's Method for Oncology

    Comparison of Current Methods and Xenogen's Method for Oncology Conventional Method (physical measurement) Xenogen’s Method (biophotonic imaging) Day 0 Not Detectable Day 14 Not Detectable Day 29 Left: 0.5 cubic cm Right: barely palpable Conventional Method Uses Multiple Groups of Animals; Xenogen M

  14. Slide 14: Animal Models

    TFF1/pS2 (trefoil peptide-1) Mup1 (major urinary protein-1, or alpha 2u globulin) ER1 (estrogen receptor-alpha) KAP (kidney androgen regulated protein) VEGF (vascular endothelial growth factor) KDR or VEGFR2 in NUDE (Nu/Nu) background KDR or VEGFR2 (vascular endothelial growth factor receptor-2) Ang

  15. Slide 15: Animal Models (cont'd)

    CP2C (Cytochrome p450, isoform 2C, human promoter) GADD153 (growth arrest and DNA damage inducible 153) GADD45B (growth arrest and DNA damage inducible 45-beta) GADD45a (growth arrest and DNA damage inducible 45-alpha) MDR1 (multiple drug resistance-1, human promoter) SOD1 (superoxide dismutase) lGC

  16. Slide 16: Integration and Innovation to Span In Vitro – In Vivo Bridge

    Integration and Innovation to Span In Vitro – In Vivo Bridge In Vitro In Vivo Cells Molecules Animals Tissue Relevance

  17. Slide 17: The Xenogen Merger - Strategic and Financial Benefits

    The Xenogen Merger - Strategic and Financial Benefits Revenue Synergies Customer synergies: academic / commercial and geographic Post-merger growth rate for combined companies expected at 10% - 15% Critical Mass Expands revenue base over 40% (2005 pro forma) Leverages manufacturing, commercial, G&A

  18. Slide 18: An Ambitious 2006

    An Ambitious 2006 2006 Goals Complete Xenogen diligence Evaluate Q1 results and revenue outlook Update full year guidance Q3 target closing Achieve 50% growth in LabChip 3000 / LabChip 90 placements Control OPEX spending and improve gross margins Achieve Q2 revenue guidance of $22 – 24M (8 - 18% gro

  19. Slide 19: Financial Summary and Performance

    Financial Summary and Performance EBITDA, as shown above, reflects net loss adjusted to exclude interest, depreciation, amortization of intangibles, FAS 123R stock compensation, and acquisition-related restructuring charges. 2001 EPS excludes effects of the Aclara litigation settlement. Value Driver

Xenogen — SPAC Merger (June 2006) on 6ix